NNC 269100

Drug Profile

NNC 269100

Latest Information Update: 27 Jun 2001

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novo Nordisk
  • Class Aminopyridines; Antiglaucomas; Organic sulfur compounds; Small molecules
  • Mechanism of Action Somatostatin receptor agonists; Somatostatin receptor subtype 4 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Glaucoma

Most Recent Events

  • 27 Jun 2001 No-Development-Reported for Glaucoma in USA (Unknown route)
  • 28 Oct 1998 Preclinical development for Glaucoma in USA (Unknown route)
  • 01 Oct 1998 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top